Capivasertib: all 52 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Immunotherapy Plus Capivasertib for Metastatic Bladder CancerNot yet recruitingNCT07793578Phase 1/2
• A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruitingNCT07343960Phase 1
• CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingNCT07294677Phase 1/2
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruitingNCT07281833Phase 3
• HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingNCT07175415Phase 1/2
• Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingNCT06607757Phase 2
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingNCT05593497Phase 2
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingNCT02523014Phase 2
• Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingNCT04493853Phase 3Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04305496Phase 3Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• OLAParib COmbinationsTerminatedNCT02576444Phase 2Results posted
• Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and TolerabilityCompletedNCT01895946Phase 1Results posted
• A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy ParticipantsCompletedNCT07241065Phase 1
• A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy ParticipantsCompletedNCT07088913Phase 1
• A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingNCT06764186Phase 3
• Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingNCT06635447Phase 3
• Effect of Capivasertib on ctDNA in ER Positive Breast CancerWithdrawnNCT06613516Phase 2
• A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)CompletedNCT05419401Phase 1
• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT05348577Phase 3
• A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid TumoursCompletedNCT04958226Phase 1
• Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy ParticipantsCompletedNCT04944771Phase 1
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• Capivasertib China PK StudyCompletedNCT04742036Phase 1
• A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the BodyCompletedNCT04712396Phase 1
• A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerCompletedNCT04087174Phase 1
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive, not recruitingNCT03997123Phase 3
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCStatus unknownNCT02525068Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line ChemotherapyCompletedNCT02451956Phase 2
• Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line ChemotherapyTerminatedNCT02449655Phase 2
• PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerCompletedNCT02423603Phase 2
• Trial of Olaparib in Combination with AZD5363 (ComPAKT)CompletedNCT02338622Phase 1
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
• Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP ChemotherapyCompletedNCT02121639Phase 1/2
• SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
• AKT Inhibitor in Oestrogen Positive Breast CancerCompletedNCT02077569Phase 2
• Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerActive, not recruitingNCT01992952Phase 1/2
• Open Label Phase 1 Study in Japan for Patient With Advanced Solid MalignanciesCompletedNCT01353781Phase 1
• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedNCT01226316Phase 1

← Capivasertib overview